Summary Twenty-five patients with advanced solid tumours were entered in a phase I/II study of six, weekly cycles of cisplatin. Nineteen patients were chemonaive and six were previously treated. The starting dose was 50 mg m-2 week-'. This dose could be escalated without major toxicity to 70 mg m-2 week-'. At a dose of 80 mg m -2 myelosuppression grade 3 occurred as well as grade I nephro-and neurotoxicity. The maximum tolerated dose was 85 mg m-2 with dose limiting thrombocytopenia. Hypertonic saline was effective in preventing nephrotoxicity. Ondansetron was a very effective antiemetic in the first weeks of treatment but its efficacy waned later on. Responses were observed in head and neck cancer, melanoma and mesothelioma. At the dose level of 80 mg m -2 the optimal dose intensity was reached. This schedule will be tested further in phase 11 studies.
Cisplatin is one of the most active and most widely used cytostatics. In vitro studies in human cancer cell lines and clinical trials in several tumour types have suggested a doseresponse relationship for cisplatin (Pillay et al., 1986; Bruckner et al., 1984; Ozols et al., 1985; Ozols, 1989; Gandara et al., 1989; Forastiere et al., 1987) . The application of high doses or frequent administration of lower doses of cisplatin is however, hampered by side effects such as severe nausea and vomiting, neurotoxicity and nephrotoxicity.
Until recently, even with the use of the most active antiemetic combination regimen (metoclopramide with lorazepam and dexamethasone), a considerable proportion of patients suffered from nausea and vomiting whereas the new 5HT3-antagonists are now found to be more effective in preventing acute nausea and vomiting induced by cisplatin (Cubbedu et al., 1990; Marty et al., 1990; Smith et al., 1990 ; de Mulder et al., 1990 ).
In addition the risk of cisplatin nephrotoxicity can be decreased by administering cisplatin in hypertonic saline 3% (Ozols et al., 1985; Gandara et al., 1989; Forastiere et al., 1987; Earhart et al., 1983) . These protective measures may theoretically allow a higher cisplatin dose intensity (D.I.). We therefore performed a phase I/II study with six weekly cycles of cisplatin, administered in 3% hypertonic saline, combined with the 5HT3-antagonist ondansetron as antiemetic. The dose intensity of cisplatin was calculated as the total amount of cisplatin administered divided by the total number of treatment weeks necessary to administer the total dose and is expressed in milligrams per square meter per week; in patients completing six treatment cycles in 6 weeks the total dose is divided by 6; in case of treatment delay the total dose administered is divided by 6 + the number of weeks delay. In those patients who did not receive the last dosage(s) due to toxicity or progressive disease the total amount of cisplatin administered was calculated over 6 weeks.
Results
Twenty-five patients were entered in the study. The patient characteristics are given in Table I (Ozols et al., 1985; Levin et al., 1987; Kaye, 1992) but is controversial in other tumour types. An improvement in treatment outcome with higher than standard cisplatin doses per course was reported for non small cell lung cancer (Gralla et al., 1981; Gandara, 1989) , testicular cancer (Samson et al., 1984; Ozols et al., 1988) and head and neck cancer (Forastiere et al., 1987) , but randomised studies comparing standard with high cisplatin dosages (in general in day 1-5 or day 1 + 8 schedules) failed to show any benefit for the high dose arms in testicular cancer (Nichols et al., 1991) , non small cell lung cancer (Einhorn et al., 1986 ) and malignant melanoma (Mortimer et al., 1991) . Another approach to increase the platinum dose intensity is to increase the frequency of cisplatin administration, or to combine cisplatin with its analogue carboplatin.
More frequent administration of cisplatin theoretically has the additional advantage that sublethally damaged tumour cells may be killed by the next dosage. Suggestive evidence to support this notion is provided by observations in poor risk germ cell tumours, where closely spaced cisplatin therapy has been investigated (Ozols et al., 1988; Horwich et al., 1989; Lewis et al., 1991) . Early studies with weekly administration of cisplatin were hampered by the side effects which can nowadays be partly prevented (Corder et al., 1977; Randolph et al., 1978) . We investigated the feasibility of weekly administration of cisplatin, with administration in 3% hypertonic saline and the concomittant use of ondansetron as preventive measures.
The starting dose was 50mg m2week' for 6 weeks. At the dose level of 85 mg m-2 week-' the dose limiting toxicity was thrombocytopenia and necessitated dosage delays in most patients jeopardising the dose intensity aimed for. The dose level of 80 mg m-2 appeared to be safe for previously untreated patients and allowed a treatment with a mean dose intensity of 70 mg m2 week-'. The severity of leucocytopenia did not differ between the two highest dose levels and grade 4 leucocytopenia was not observed (Table III) . The risk of nephrotoxicity with this schedule is low as is the risk of neurotoxicity. The risk of ototoxicity, however, is higher than with standard cisplatin schedules and is in this study comparable to other dose intense cisplatin regimens. Nausea and vomiting could be effectively prevented by ondansetron in the first 3-4 weeks of treatment especially at dosages lower than 80 mg m-2. However, with continuation of treatment the efficacy of ondansetron gradually waned. Nevertheless we conclude that weekly administration of cisplatin for a period of 6 weeks is feasible and when administered in hypertonic saline and combined with a 5-HT3 antagonist a higher dose intensity can be reached than with previously reported weekly schedules or with schedules combining cisplatin and carboplatin. Higano et al. (1991) also administered cisplatin on a weekly schedule in non small cell lung cancer but failed to reach a high response rate; in this study weekly cisplatin was combined with mitomycin C, vinblastin and fluorouracil which hampered the cisplatin dose intensity reached which was approximately 40-44mg m2weekl'. Studies with the combination of cisplatin and carboplatin also appear to have resulted in dose intensities lower than we achieved with single agent cisplatin (Calvert, 1991) . Assuming a 'normal' surface area of 1.7 mg2 and a GFR of 100mg min-' Calvert (1991) calculated an AUC of 1 unit of carboplatin per week to be equivalent in dose intensity to 18.4 mg m-2 of cisplatin per week. Using this formula the cisplatin equivalent dose intensities varied in the cisplatin plus carboplatin studies from 36-63 mg m-2 week'-l (Trump et al., 1987; Kreisman et al., 1990; Dimery et al., 1991; Gill et al., 1991; Sessa et al., 1991) , with the highest dose intensity only achieved during the first treatment cycle (Hardy et al., 1991) . These dose intensities compare unfavourable with the dose intensity that we achieved for the whole treatment period of six cycles. The highest dose intensity reached in 5-day regimens every 4 weeks is 50 mg m-2 week-' (Ozols, 1989) again lower than we achieved. The encouraging results we observed in head and neck cancer and mesothelioma warrant further exploration in phase II studies. The dosage for these studies is 80 mg m2 week-' for 6 weeks in previously untreated patients. However, it is obvious that randomised studies comparing these new schedules with standard schedules of cisplatin administration are required to establish the clinical benefit.
